Optimizing systemic therapy selection in metastatic colorectal cancer

Axel F Grothey

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.

Original languageEnglish (US)
Pages (from-to)682-685
Number of pages4
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume13
StatePublished - May 1 2015

Fingerprint

Colorectal Neoplasms
Therapeutics
Epidermal Growth Factor Receptor
Vascular Endothelial Growth Factor A
Drug Therapy
Mutation
Antibodies

ASJC Scopus subject areas

  • Oncology

Cite this

Optimizing systemic therapy selection in metastatic colorectal cancer. / Grothey, Axel F.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 13, 01.05.2015, p. 682-685.

Research output: Contribution to journalArticle

@article{df7c5d79ea1b42e5a9159aa3985c2382,
title = "Optimizing systemic therapy selection in metastatic colorectal cancer",
abstract = "For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.",
author = "Grothey, {Axel F}",
year = "2015",
month = "5",
day = "1",
language = "English (US)",
volume = "13",
pages = "682--685",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",

}

TY - JOUR

T1 - Optimizing systemic therapy selection in metastatic colorectal cancer

AU - Grothey, Axel F

PY - 2015/5/1

Y1 - 2015/5/1

N2 - For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.

AB - For metastatic colorectal cancer, many effective agents can be incorporated into multiple lines of therapy across the nearly 3-year continuum of treatment. Emphasis should be on using all the recommended agents, with extended duration of anti-vascular endothelial growth factor treatment, and on identifying patients with any mutation in the RAS pathway. Chemotherapy plus bevacizumab or an epidermal growth factor receptor antibody are both viable options as first-line therapy in patients with RAS wild-Type disease.

UR - http://www.scopus.com/inward/record.url?scp=84996522101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84996522101&partnerID=8YFLogxK

M3 - Article

VL - 13

SP - 682

EP - 685

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

ER -